Current status of therapy for breast cancer worldwide and in Japan

Figure 5 ABCSG-05 trial. Kaplan-Meier estimates of overall survival (OS) (A) and relapse-free survival (RFS) (B) in the group assigned to endocrine therapy (tamoxifen and goserelin) and the group assigned to chemotherapy. Differences between groups were not significant. A: P = 0.093, generalized Wilcoxon test; P = 0.195, log-rank test. Figures of patients at risk are included. (Source: Figure 1 in reference 5); B: P = 0.017, generalized Wilcoxon test; P = 0.037, log-rank test. Figures of patients at risk are included. (Source: Figure 2 in reference 5).